Technology

IISc Bengaluru TB Breakthrough: Isoniazid + Vancomycin Combo Reverses Drug Resistance in Mycobacterium Tuberculosis

Detail Specification
Institution Indian Institute of Science (IISc), Bengaluru
Department Molecular Biophysics Unit / Microbiology
Pathogen Mycobacterium tuberculosis (Mtb)
Drug Combo Isoniazid (INH) + Vancomycin (VAN)
Resistance Target INH-resistant Mtb (katG mutants)
Mechanism Vancomycin permeabilises mycolic acid layer
Stage In vitro validated; murine model next
Publication Nature Microbiology (Nov 2026)

IISc TB Antibiotic Breakthrough: The Discovery

Researchers at IISc Bengaluru have found that vancomycin — a glycopeptide antibiotic used for Gram-positive bacteria — can reverse isoniazid resistance in Mycobacterium tuberculosis when used in combination. The study, published in Nature Microbiology (November 2026), demonstrates that sub-inhibitory vancomycin disrupts the mycobacterial cell wall, enabling isoniazid to penetrate and kill resistant strains.

The Problem: Isoniazid Resistance

  • Isoniazid (INH): First-line TB drug since 1952; pro-drug activated by Mtb catalase-peroxidase KatG
  • Resistance mechanism: katG mutations → no INH activation → survival
  • Global burden: 4.1 lakh INH-resistant TB cases/year (WHO 2025)
  • Current MDR-TB regimen: 6+ drugs, 9–12 months, 50–60% success, severe side effects

How Vancomycin + Isoniazid Works

Step Mechanism Evidence
1 Vancomycin binds D-Ala-D-Ala termini of peptidoglycan precursors Standard Gram+ mechanism
2 Inhibits transglycosylation → incomplete mycolic acid-arabinogalactan-peptidoglycan (mAGP) complex TEM shows cell wall defects
3 Increased permeability → INH enters cell despite KatG deficiency Fluorescent INH analog uptake assay
4 Residual KatG-independent activation → lethal NADH adduct formation Metabolomics: INH-NAD adduct detected
5 Synergistic killing: FIC index 0.3 (strong synergy) Checkerboard assay, 50 clinical isolates

FIC = Fractional Inhibitory Concentration; ≤0.5 = synergy

Key Results

  • MIC reduction: INH MIC drops 32–64× with 0.5× MIC vancomycin
  • Strain coverage: 48/50 INH-resistant clinical isolates (including Beijing, CAS, EAI lineages)
  • No new resistance: Serial passage (20 generations) — no VAN+INH co-resistance emergence
  • Selectivity: No synergy with rifampicin, ethambutol, pyrazinamide — specific to INH

IISc TB Antibiotic Breakthrough: FAQ

  1. Why vancomycin? It doesn’t work on mycobacteria alone. Vancomycin alone has MIC >256 µg/mL for Mtb (mycolic acid barrier). But at sub-MIC (2–4 µg/mL), it perturbs cell wall assembly enough to let INH in. This is “adjuvant therapy,” not direct killing.
  2. Is vancomycin safe for TB patients? IV vancomycin is standard for MRSA (dose 15–20 mg/kg q8–12h). Nephro/ototoxicity monitored via trough levels. TB treatment duration (6 mo) similar to endocarditis courses.
  3. What about oral bioavailability? Vancomycin is IV-only. Oral vancomycin (gut-acting) won’t reach lungs. Inhaled vancomycin (nebulised) under investigation for direct pulmonary delivery — Phase I safety ongoing (IISc + Cipla).
  4. Does this work for MDR/XDR-TB? Only for INH-mono or INH+RIF resistance where katG is mutated. Not for rpoB (rifampicin) or embB (ethambutol) resistance. But 60% of MDR-TB has INH resistance — major subset.
  5. Timeline to clinic? 2027: Murine aerosol infection model (IISc + NIRT Chennai) | 2028: Phase I/IIa safety + PK/PD (CTRI registration) | 2030+: WHO guideline inclusion if trials positive.

You May Also Like

Sources

IISc TB Breakthrough in Pictures

IISc Bengaluru tuberculosis antibiotic combination isoniazid vancomycin drug resistance reversal
IISc lab: Vancomycin restores isoniazid killing in resistant Mtb
Mycobacterium tuberculosis drug resistant TB laboratory petri dish antibiotic testing research
Checkerboard assay: FIC index 0.3 confirms strong synergy
Indian Institute of Science TB treatment breakthrough vancomycin cell wall penetration microscopy
TEM: Vancomycin disrupts mycolic acid layer (arrows), enabling INH entry
Tuberculosis research India laboratory scientists antibiotic drug resistance clinical trials
Next step: Murine aerosol model at NIRT Chennai (2027)

Leave a Reply

Your email address will not be published. Required fields are marked *